Results 41 to 50 of about 4,027 (165)

Interferon‐induced transmembrane (IFITM) proteins at the tumour–immune interface: A four‐axis framework for their context‐dependent roles

Clinical and Translational Medicine, Volume 16, Issue 8, August 2026.
Interferon‐induced transmembrane (IFITM) function in cancer is set by four contextual coordinates, not by family membership. Acute interferon input drives major histocompatibility complex class I (MHC‐I)‐linked immunogenicity; chronic input drives programmed death‐ligand 1 (PD‐L1)‐coupled resistance.
Zhe Liu, Jie Meng, Zengyan Lai, Fuqiu Li, Sha Lv   +4 more
wiley   +1 more source

Bilateral Giant Plexiform Neurofibromas In Neurofibromatosis Type 1

Indian Journal of Dermatology, 2002
A single plexiform neurofibroma or two of any type are considered diagnostic of neurofibromatosis type 1 (NF). Plexiform neurofibromas are congenital and pathognomonic for NF-1.
Thappa D . M, Jeevankumar B, Karthikeyan K   +2 more
doaj  

DNA Hypomethylation Is Not Cell Intrinsically Toxic to Polycomb Repressive Complex 2 Deficient Malignant Peripheral Nerve Sheath Tumors

Genes, Chromosomes and Cancer, Volume 65, Issue 8, August 2026.
ABSTRACT Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive soft tissue sarcomas and the most common cause of disease‐associated death for neurofibromatosis type 1 (NF1) patients. In the context of NF1, MPNSTs develop from benign premalignant precursors and the transition to malignancy is typically accompanied by loss of the polycomb ...
Madilyn R. Stahl, Christopher M. Stehn, Zachary J. Seeman, Christopher Faulk, David A. Largaespada   +4 more
wiley   +1 more source

Solitary Nodule in the Hard Palate

Oral Diseases, EarlyView.
Sara Lia Gonçalves de Lima, Poliana Soares Cruz, Maria Gabriela Candido Dias, Láysa Tavares de Melo, Laura Maria dos Santos Reis Rocha de Castro, Felipe Paiva Fonseca, Brunno Santos de Freitas Silva   +6 more
wiley   +1 more source

Selumetinib as a Target Therapy in Progressive Paediatric Low‐Grade Gliomas—Case Series (pLGG)

Journal of Paediatrics and Child Health, Volume 62, Issue 8, Page 1499-1508, August 2026.
ABSTRACT Background Optic pathway gliomas (OPGs) occur in 15%–20% of children with neurofibromatosis type 1 (NF1). While smaller gliomas may be only monitored, the current standard of care for symptomatic ones relies on chemotherapy, most commonly carboplatin and vincristine.
Laura Trapani, Giulia Gortani, Andrea Magnolato, Flora Maria Murru, Elisabetta Cattaruzzi, Laura Diplotti, Paola Michieletto, Silvia Giganti, Davide Zanon, Alessandra Maestro, Valentina Kiren, Egidio Barbi, Irene Bruno   +12 more
wiley   +1 more source

Facial plexiform neurofibroma in a child with neurofibromatosis type I: A case report

Journal of Indian Society of Pedodontics and Preventive Dentistry, 2007
Plexiform neurofibroma is a non-circumscribed, thick, and irregular benign tumor of the peripheral nerve sheath. It is a virtually pathognomonic and often disabling feature of neurofibromatosis type I.
Patil K, Mahima V, Shetty S, Lahari K
doaj  

A Diagnostic Challenge: Unilateral Gingival Enlargement With Altered Tooth Eruption in a Paediatric Patient

Oral Diseases, EarlyView.
Luca Cricenti, Rossella Ninivaggi, Federico Liguori, Nicola Scotti, Allegra Comba, Patrizia Defabianis, Federica Romano   +6 more
wiley   +1 more source

Personalized Selumetinib Dosing in Pediatric Neurofibromatosis Type 1: Insights From a Pilot Therapeutic Drug Monitoring Study

Pediatric Blood &Cancer, Volume 73, Issue 7, July 2026.
ABSTRACT Objective To evaluate selumetinib exposure using therapeutic drug monitoring (TDM) in pediatric patients with neurofibromatosis type 1 (NF1) and plexiform neurofibromas (PN), assess interpatient pharmacokinetic variability, and explore the relationship between drug exposure, clinical response, and adverse effects.
Janka Kovács, Zoltán Köllő, Balázs Gellért Karvaly, Mahmoud Obeidat, Rita Nagy, Péter Hegyi, Brigitta Teutsch, Eszter Tuboly, Miklós Garami   +8 more
wiley   +1 more source

Cutaneous Adverse Drug Reactions Associated With BRAF and MEK Inhibitors: A Real‐World Analysis of WHO Pharmacovigilance Data

Clinical Pharmacology &Therapeutics, Volume 120, Issue 1, Page 274-285, July 2026.
BRAF inhibitors and MEK inhibitors (MEKi) have reshaped the treatment of BRAFV600‐mutant malignancies; however, cutaneous adverse drug reactions (ADRs) remain a frequent and clinically impactful toxicity. Although clinical trials provide insight into their safety profiles, real‐world data on dermatologic ADRs are limited.
Natalia Sauer, Piotr Giedziun, Jacek Calik, Anna Wiela‐Hojeńska   +3 more
wiley   +1 more source

Multidimensional ultrasound and computed tomography imaging support in bleeding plexiform neurofibromatosis of the scalp: A case report and literature review

Indian Journal of Dermatology, 2015
Active bleeding in plexiform neurofibromatosis can be a life-threatening complication in neurofibromatosis type 1 (NF1). The prompt imaging support of 2D-3D ultrasound (US) and computed tomography (CT) during the active hemorrhage phase of cutaneous ...
Ximena Wortsman, Nelson Lobos, Rodrigo De la Parra, Laura Carreno   +3 more
doaj   +1 more source